Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Production & Manufacturing
Manufacturing
Return to: PBR Home | Production & Manufacturing | Manufacturing

Manufacturing

Bristol-Myers Squibb to divest Irish manufacturing facility to SK Biotek Bristol-Myers Squibb has agreed to divest its small molecule active pharmaceutical ingredient manufacturing facility in Swords, Ireland, to South Korea based SK Biotek, a subsidiary of SK Holdings.
Production & Manufacturing > Manufacturing > News
JSR Life Sciences to buy cell line developer Selexis By PBR Staff Writer
JSR Life Sciences (JLS) has agreed to acquire life sciences firm and mammalian cell-line generation technologies provider Selexis for an undisclosed sum.
Production & Manufacturing > Manufacturing > News FDA accepts Synergy’s sNDA for Trulance to treat adults with IBS-C The US Food and Drug Administration (FDA) has accepted Synergy Pharmaceuticals’ supplemental New Drug Application (sNDA) Trulance (plecanatide) for the treatment of adults with irritable bowel syndrome with constipation (IBS-C).
Production & Manufacturing > Manufacturing > News
See more Manufacturing news

Latest Manufacturing News and Insight

View all Manufacturing news or find news targeted to your interests
JSR Life Sciences to buy cell line developer Selexis
By PBR Staff Writer
JSR Life Sciences (JLS) has agreed to acquire life sciences firm and mammalian cell-line generation technologies provider Selexis for an undisclosed sum.
Production & Manufacturing > Manufacturing > News
FDA accepts Synergy’s sNDA for Trulance to treat adults with IBS-C
The US Food and Drug Administration (FDA) has accepted Synergy Pharmaceuticals’ supplemental New Drug Application (sNDA) Trulance (plecanatide) for the treatment of adults with irritable bowel syndrome with constipation (IBS-C).
Production & Manufacturing > Manufacturing > News
AstraZeneca to divest Zomig migrane drug rights for $302m
By PBR Staff Writer
German firm Grünenthal Group has agreed to acquire global rights of migraine treatment, Zomig (Zolmitriptan), from AstraZeneca for around $302m.
Production & Manufacturing > Manufacturing > News
View all Manufacturing news or find news targeted to your interests